Is adagrasib available on the market?

In February 2022, the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for Adagrasib for the treatment of patients with KRAS G12C-positive non-small cell lung cancer (NSCLC) who have previously received treatment. In December 2022, the U.S. Food and Drug Administration (FDA) approved adagrasib for the accelerated treatment of patients with locally advanced or metastatic non-small cell lung cancer with KRAS G12C mutations. Adagrasib joins sotorasib to become another KRAS G12C inhibitor approved by the FDA.

Adagrasiib is a potent oral small molecule covalent inhibitor of KRASG12C that irreversibly and selectively binds to KRASG12C in its inactive GDP-bound state. Adagrasiib has favorable properties, including long half-life (23 hours), dose-dependent pharmacokinetics, and central nervous system (CNS) penetration. The clinical activity of adagrasib has been found in patients with krasg12c-mutated solid tumors, and results from the KRYSTAL-1 study showed that the objective response rate (ORR) in patients with KRASG12C-mutated NSCLC was 43%. In multiple preclinical CNS metastasis models, adagrasib has been shown to penetrate into the cerebrospinal fluid, resulting in tumor regression and prolonged survival.

Sinceadagrasibthe original drug has not yet been launched in China, patients can only purchase adagrasib through overseas channels, and the U.S. original version of 200mg*180 tablets is priced at hundreds of thousands of yuan per box (the price may fluctuate due to exchange rates), which is very expensive. Currently, there are no generic drugs of adagrasib produced overseas. For more drug information and specific prices, please consult Yaode’s medical consultant.